Morita Yasuyoshi

モリタヤスヨシ | Morita Yasuyoshi

Affiliation and department：
Job title： Associate Professor

Research field (1)： Hematology and oncology

Research theme for competitive and other funds (6)：

2023 - 2026 変異受容体型チロシンキナーゼの細胞内輸送制御による白血病治療薬の開発研究
2022 - 2025 治癒を目指したCML幹細胞の特性解析
2020 - 2023 多発性骨髄腫の病態形成に関わる抗腫瘍免疫機構の解析研究
2018 - 2021 Characterization molecular and immunologic features of CML stem cells for treatment-free remission.
2016 - 2019 Analysis of novel pathogenesis caused by disorder of immature hematopoietic cells in multiple myeloma

Show all

Papers (109)：

Kensuke Usuki, Toshihiro Miyamoto, Takuji Yamauchi, Kiyoshi Ando, Yoshiaki Ogawa, Masahiro Onozawa, Takahiro Yamauchi, Hitoshi Kiyoi, Akira Yokota, Takayuki Ikezoe, et al. A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia. International journal of hematology. 2024
Takahiro Haeno, Shinya Rai, Yoshiaki Miyake, Maiko Inoue, Ko Fujimoto, Aki Fujii, Yoshio Iwata, Shuji Minamoto, Takahide Taniguchi, Hiroaki Kakutani, et al. Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma. Journal of clinical and experimental hematopathology : JCEH. 2023. 63. 2. 99-107
Ryosuke Fujiwara, Yasuhiro Taniguchi, Shinya Rai, Yoshio Iwata, Aki Fujii, Ko Fujimoto, Takahiro Kumode, Kentaro Serizawa, Yasuyoshi Morita, J Luis Espinoza, et al. Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells. Biochemical and biophysical research communications. 2022. 626. 156-166
Yasuyoshi Morita, Yasuhito Nannya, Motoshi Ichikawa, Hitoshi Hanamoto, Hirohiko Shibayama, Yoshinobu Maeda, Tomoko Hata, Toshihiro Miyamoto, Hiroshi Kawabata, Kazuto Takeuchi, et al. ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial. International journal of hematology. 2022. 116. 5. 659-668
Chikashi Yoshida, Takeshi Kondo, Tomoki Ito, Masahiro Kizaki, Kazuhiko Yamamoto, Toshihiro Miyamoto, Yasuyoshi Morita, Tetsuya Eto, Yuna Katsuoka, Naoki Takezako, et al. Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy. International journal of hematology. 2022. 116. 1. 89-101

ｍore...

MISC (67)：

口分田貴裕, 頼晋也, 波江野高大, 角谷宏明, 源周治, 綿谷陽作, 芹澤憲太郎, 谷口康博, 森田泰慶, 田中宏和, et al. Gilteritinib treatment for extramedullary relapse of FLT3-ITD acute myeloid leukemia. 日本造血細胞移植学会総会プログラム・抄録集. 2021. 43rd
谷口康博, 平瀬主税, 芦田隆司, 波江野高大, 角谷宏明, 源周治, 綿谷陽作, 口分田貴裕, 芹澤憲太郎, 頼晋也, et al. Clinical usefulness of Letermovir for patients with stem cell transplantation. 日本造血細胞移植学会総会プログラム・抄録集. 2021. 43rd
角谷宏明, 口分田貴裕, 源周治, 頼晋也, 森田泰慶, 田中宏和, 芦田隆司, 松村到. CMML様の病型移行を来したMDSに対してアザシチジンが有効であった1例. 臨床血液. 2021. 62. 3
谷口康博, 芦田隆司, 森田泰慶, 平瀬主税, 頼晋也, 中山聖子, 芹澤憲太郎, 口分田貴裕, 井上宏昭, 岩田吉男, et al. Outcomes of allo-SCT for patients in non-remission especially with chemoresistance. 日本造血細胞移植学会総会プログラム・抄録集. 2020. 42nd
鳥畑さやか, 江原裕基, 助臺美帆, 下出孟史, 金澤仁美, 守屋実央, 安武夏海, 兵頭咲紀, 小森舞子, 源周治, et al. Efficacy of dental extraction in patients with oral diseases prior to allogeneic hematopoietic stem cell transplantation. 日本造血細胞移植学会総会プログラム・抄録集. 2020. 42nd

ｍore...

Lectures and oral presentations (113)：

副腎不全を契機に診断した両側性副腎原発悪性リンパ腫の1例
(臨床血液 2017)
腹水貯留にて発症したprimary effusion lymphoma-like diffuse large B-cell lymphomaの1例
(臨床血液 2017)
リツキシマブによる間質性肺炎をきたしたDLBCLの1例
(臨床血液 2017)
多発性骨髄腫のpoor mobilizerに対するplerixafor併用下でのPBSCH
(日本輸血細胞治療学会誌 2016)
同種造血幹細胞移植後に再発した骨髄異形成症候群(MDS)におけるAzacitidine(AZA)療法
(臨床血液 2016)

ｍore...

Education (1)：

- 現在 Kindai University Faculty of Medicine

Professional career (1)：

医学博士 (近畿大学)

Committee career (1)：

- 現在日本血液学会評議員

Association Membership(s) (3)：

THE JAPAN SOCIETY FOR TRANSPLANTATION , THE JAPANESE SOCIETY OF HEMATOLOGY , THE JAPANESE SOCIETY OF INTERNAL MEDICINE

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page